Related Experiment Video
Updated: Jun 22, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease
Young-Hak Kim1, Seong-Wook Park, Seung-Whan Lee
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Insights
Sirolimus-eluting stents (SES) significantly reduced restenosis and revascularization needs in long coronary lesions compared to paclitaxel-eluting stents (PES). This finding offers improved outcomes for patients undergoing coronary interventions for complex lesions.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Coronary interventions for long lesions have suboptimal outcomes.
- Drug-eluting stents aim to improve these outcomes.
- Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) are commonly used.
Purpose of the Study:
- To compare the efficacy of SES versus PES in treating long native coronary artery lesions.
- To evaluate restenosis rates and the need for revascularization.
Main Methods:
- A randomized, multicenter, prospective study involving 500 patients.
- Patients received either SES or PES for long coronary lesions (>= 25 mm).
- Primary endpoint was in-segment restenosis at 6-month follow-up angiography.
Main Results:
- SES demonstrated significantly lower in-segment binary restenosis rates (3.3% vs. 14.6%, P<0.001) compared to PES.
- In-stent late lumen loss was significantly lower with SES (0.09 mm vs. 0.45 mm, P<0.001).
- SES group showed a reduced rate of target-lesion revascularization at 9 months (2.4% vs. 7.2%, P=0.012).
Conclusions:
- SES implantation is superior to PES for long native coronary artery lesions.
- SES reduces angiographic restenosis and the need for target-lesion revascularization.
- No significant difference in death or myocardial infarction rates between the groups.
Background:
Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. This study compared sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for long coronary lesions.
Methods And Results:
The present randomized, multicenter, prospective study compared the use of long (> or =32 mm) SES with PES in 500 patients with long (> or =25 mm) native coronary lesions. The primary end point of the trial was the rate of binary in-segment restenosis according to follow-up angiography at 6 months. The SES and PES groups had similar baseline characteristics. Lesion length was 33.9+/-11.6 mm in the SES group and 34.5+/-12.6 mm in the PES group (P=0.527). The in-segment binary restenosis rate was significantly lower in the SES group than in the PES group (3.3% versus 14.6%; relative risk 0.23; P<0.001). In-stent late loss of lumen diameter was 0.09+/-0.37 mm in the SES group and 0.45+/-0.55 mm in the PES group (P<0.001). In patients with restenoses, a pattern of focal restenosis was more common in the SES group than in the PES group (100% versus 53.3%, P=0.031). Consequently, SES patients had a lower rate of target-lesion revascularization at 9 months (2.4% versus 7.2%, P=0.012). The incidence of death (0.8% in SES versus 0% in PES, P=0.499) or myocardial infarction (8.8% in SES versus 10.8% in PES, P=0.452) at 9 months of follow-up was not statistically different between the 2 groups.
Conclusions:
For patients with long native coronary artery disease, SES implantation was associated with a reduced incidence of angiographic restenosis and a reduced need for target-lesion revascularization compared with PES implantation.
More Related Videos
Related Concept Videos
Mitral Stenosis IV: Nursing Management
Pericarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

